Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8,283 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England.
Lee D, Amadi A, Sabater J, Ellis J, Johnson H, Kotapati S, McNamara S, Walker A, Cooper M, Patterson K, Roskell N, Meng Y. Lee D, et al. Among authors: meng y. Pharmacoecon Open. 2019 Mar;3(1):43-54. doi: 10.1007/s41669-018-0080-5. Pharmacoecon Open. 2019. PMID: 29790020 Free PMC article.
Correction to: Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England.
Lee D, Amadi A, Sabater J, Ellis J, Johnson H, Kotapati S, McNamara S, Walker A, Cooper M, Patterson K, Roskell N, Meng Y. Lee D, et al. Among authors: meng y. Pharmacoecon Open. 2019 Mar;3(1):127. doi: 10.1007/s41669-018-0096-x. Pharmacoecon Open. 2019. PMID: 30206825 Free PMC article.
Cost-effectiveness of Pembrolizumab versus Carboplatin-based Chemotherapy as First-line Treatment of PD-L1-positive Locally Advanced or Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Therapy in the United States.
Hale O, Patterson K, Lai Y, Meng Y, Li H, Godwin JL, Homet Moreno B, Mamtani R. Hale O, et al. Among authors: meng y. Clin Genitourin Cancer. 2021 Feb;19(1):e17-e30. doi: 10.1016/j.clgc.2020.07.006. Epub 2020 Jul 16. Clin Genitourin Cancer. 2021. PMID: 32826180 Free article.
A review and validation of overall survival extrapolation in health technology assessments of cancer immunotherapy by the National Institute for Health and Care Excellence: how did the initial best estimate compare to trial data subsequently made available?
Bullement A, Meng Y, Cooper M, Lee D, Harding TL, O'Regan C, Aguiar-Ibanez R. Bullement A, et al. Among authors: meng y. J Med Econ. 2019 Mar;22(3):205-214. doi: 10.1080/13696998.2018.1547303. Epub 2018 Nov 30. J Med Econ. 2019. PMID: 30422080 Free article. Review.
8,283 results